Clinical Study

A Phase 3 Double-Blind, Placebo Controlled, Parallel Group Study Of A Disease Modifying Agent In Subjects With Early Parkinson Disease

Posted Date: Jun 14, 2017

  • Investigator: Alok Sahay
  • Co-Investigator: Emily Shanks
  • Specialties: Parkinson's Disease, Neurology, Movement Disorders
  • Type of Study: Drug

The purpose of this study is to determine if an investigational drug called isradipine is safe and helpful in slowing the rate of PD decline. Isradipine has been approved by the Food and Drug Administration (FDA) to treat high blood pressure but is consi


You Are Being Asked To Take Part In This Research Study Because You Have Been Diagnosed With Parkinson’S Disease In The Last Three Years, Were At Least 30 Years Old When You Were Diagnosed, And It Is Expected That You Will Not Need Medications To Treat Th


Sahay, Early Stages Of Parkinson's Disease, Newly Diagnosed, Isradipine, Parkinson's Disease

For More Information:

Hilary Perez
(513) 558-0112

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.